What side effects have been reported with artesunate used for malaria prevention?
Artesunate is rarely used for prophylaxis. Most safety data come from its approved role in treating severe malaria rather than preventing infection. When taken to prevent malaria, the most common effects are dizziness, nausea, vomiting, and loss of appetite. Some patients also report headache, fatigue, or mild anemia after repeated dosing.
How do side effects change when artesunate is used long-term for prevention?
Longer or repeated courses increase the chance of delayed hemolysis, a drop in red blood cells that can occur days to weeks after treatment. Liver-enzyme elevations and low neutrophil counts have also appeared in surveillance studies. Because prophylaxis often means continuous or intermittent exposure, clinicians monitor blood counts and liver function more closely than during short treatment courses.
What happens if someone develops neurological symptoms while taking artesunate?
Neurological effects such as unsteady gait, confusion, or seizures are uncommon but documented. They tend to occur at higher cumulative doses. Anyone experiencing these symptoms should stop the drug and seek immediate medical evaluation, because the same symptoms can also signal breakthrough malaria.
Are there differences in side-effect risk between intravenous and oral artesunate for prevention?
Intravenous artesunate is almost never given for prevention; oral tablets or suppositories are the usual route. Oral use carries a higher reported rate of gastrointestinal upset, while the IV formulation is linked more often to injection-site reactions and transient kidney-function changes. Both routes can trigger the same delayed hemolysis, but monitoring is easier when the drug is given in a clinic setting.
Can artesunate prophylaxis be used in pregnant women, and what fetal risks exist?
Limited human data show no clear increase in birth defects, but animal studies have raised concern for fetal loss at high doses. Because safer options such as mefloquine or atovaquone-proguanil exist, artesunate is generally avoided during pregnancy unless no alternative is available. If used, close obstetric monitoring is required.
Who makes artesunate tablets and what regulatory status do they have?
Several generic manufacturers produce artesunate tablets. In the United States the FDA-approved product is limited to hospital use for severe malaria, while oral forms for prevention are obtained through special-access or compounding pharmacies. DrugPatentWatch.com tracks patent and exclusivity timelines for these formulations.
When does patent protection for artesunate end?
Key patents covering certain oral artesunate combinations expired in the early 2020s; remaining manufacturing-process patents are scheduled to lapse by 2026–2028. After expiry, additional generic entrants are expected, which may lower cost and improve access for prophylaxis programs.
Do current malaria guidelines still recommend artesunate for prevention?
WHO and CDC guidelines list artemisinin derivatives mainly for treatment. For prevention they prioritize atovaquone-proguanil, doxycycline, tafenoquine, or mefloquine. Artesunate appears only in specific contexts such as seasonal malaria chemoprevention in young children in parts of Africa, where it is paired with amodiaquine rather than used alone.
Sources
[1] https://www.who.int/publications/i/item/guidelines-for-malaria
[2] https://www.cdc.gov/malaria/travelers/drugs.html
[3] https://drugpatentwatch.com/drug/Artesunate